Addressing an Unmet Need in EGFR mNSCLC
Current Recommendations on Managing Dermatologic Adverse Reactions Associated With Amivantamab Therapy for mNSCLC
Disclaimer: On August 19, 2024, the FDA approved lazertinib (Lazcluze) in combination with amivantamab-vmjw (Rybrevant) for the first-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R substitution mutations, as detected by an FDA-approved test.
Login to view comments.
Click here to Login
